Cantor Fitzgerald initiated coverage of Astria Therapeutics (ATXS) with an Overweight rating and $47 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics price target raised to $28 from $27 at Wedbush
- Astria Therapeutics Advances Clinical Trials and Financials
- Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating
- Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating
- Buy Rating for Astria Therapeutics: Promising Clinical Advancements and Strong Financial Position